Silo Pharma, Inc. Logo

Silo Pharma, Inc.

Develops novel psychedelic & traditional therapies for pain and central nervous system disorders.

SILO | US

Overview

Corporate Details

ISIN(s):
US82711P2011 (+1 more)
LEI:
Country:
United States of America
Address:
677 N. WASHINGTON BLVD, 34236 SARASOTA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on creating novel formulations of traditional and psychedelic therapeutics. The company targets underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Its portfolio includes programs such as SPC-15 for PTSD and SP-26 for fibromyalgia, as well as preclinical assets for Alzheimer’s disease and multiple sclerosis. Silo Pharma utilizes the streamlined 505(b)(2) regulatory pathway to potentially lower costs and accelerate FDA approval. The company develops its intellectual property through exclusive collaborations with leading universities and research partners.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Silo Pharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Silo Pharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Silo Pharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America CTXR
CJ Bioscience Logo
Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.
South Korea 311690
CKD Bio Corp. Logo
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea 063160
Clearmind Medicine Inc. Logo
Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.
United States of America CMND
Clearside Biomedical, Inc. Logo
Developing therapies for back-of-the-eye diseases via proprietary suprachoroidal delivery.
United States of America CLSD
Clene Inc. Logo
Developing nanocrystal therapies for neurodegenerative diseases like ALS and MS.
United States of America CLNN

Talk to a Data Expert

Have a question? We'll get back to you promptly.